Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On March 20, 2025, MetaVia Inc. (MTVA) announced financial results for 2024 and provided a business update.</li><li>We anticipate topline results from the multiple ascending dose (MAD) Part 2 of the Phase 1 trial of DA-1726 to be reported in April 2025.</li><li>DA-1726 is the company's novel dual oxyntomodulin analog that functions as a dual glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) agonist.</li></ul>

On March 20, 2025, MetaVia Inc. (MTVA) announced financial results for 2024 and provided a business update.We anticipate topline results from the multiple ascending dose (MAD) Part 2 of the Phase 1 trial of DA-1726 to be reported in April 2025.DA-1726 is the company's novel dual oxyntomodulin analog that functions as a dual glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) agonist.

MTVA: 비만에 대한 DA-1726의 1상 2부 데이터가 곧 나올 것으로 예상 